Transcriptional Regulation of CYP2D6 by Nrf2 and Its Implications in Breast Cancer Therapy: Bioinformatics and Experimental Evidence
Abstract
BACKGROUND: Tamoxifen (TAM) resistance in patient with breast cancer is the leading cause of mortality among women globally. Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of TAM, and recently NF-E2-related factor 2 (Nrf2) has recently been found as its regulator. However, the impact of Nrf2-mediated CYP2D6 regulation in the context of breast cancer and TAM resistance are currently unknown. Therefore, this study was conducted to examine the role of CYP2D6 and Nrf2 in breast cancer prognosis.
MEDTHODS: The roles of CYP2D6 and Nrf2 were investigated in the T47D breast cancer cell line and T47D-derived TAM-resistant cells by examining the gene expression, cell viability, and transcriptional regulation by quantitative reverse transcription polymerase chain reaction (qRT-PCR), MTT, and reporter gene assay, respectively. Additionally, comprehensive in silico analysis of the transcriptomic and clinical data from The Cancer Genome Atlas database were performed to uncover the prognostic role of CYP2D6 and its regulator in breast cancer patients.
RESULTS: CYP2D6 mRNA was low and Nrf2 protein was high in TAM-resistant T47D cells compared to parental cells. Nrf2 knockdown upregulated CYP2D6 mRNA levels and enhanced the cytotoxicity of TAM. Similarly, in silico analysis revealed that low CYP2D6 mRNA and high Nrf2 protein were related to a lower probability of survival. The rs1238662089 within the identified Nrf2-binding site was found to greatly affect CYP2D6 expression levels, indicating its role as predictor for better prognosis.
CONCLUSION: This study revealed for the first time that Nrf2 regulates CYP2D6expression in breast cancer and is involved in TAM sensitivity; thus, plays a role in breast cancer patient prognosis.KEYWORDS: breast cancer, CYP2D6, Nrf2, pharmacoepigenetics, SNPs
Full Text:
PDFReferences
Alzahrani AM, Rajendran P. The multifarious link between cytochrome P450s and cancer. Oxid Med Cell Longev. 2020; 2020: 3028387, CrossRef.
Siswanto FM, Firmasyah RD, Handayani MDN, Oguro A, Imaoka S. Nrf2 regulates the expression of CYP2D6 by inhibiting the activity of krüppel-like factor 9 (KLF9). Curr Drug Metab. 2023; 24(9): 667-81, CrossRef.
Caudle KE, Sangkuhl K, Whirl‐Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP 2D6 genotype to phenotype translation: Consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group. Clin Transl Sci. 2020; 13(1): 116-24, CrossRef.
Mulder TAM, de With M, del Re M, Danesi R, Mathijssen RHJ, van Schaik RHN. Clinical CYP2D6 genotyping to personalize adjuvant tamoxifen treatment in ER-positive breast cancer patients: Current status of a controversy. Cancers. 2021; 13(4): 771, CrossRef.
He W, Grassmann F, Eriksson M, Eliasson E, Margolin S, Thorén L, et al. CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in patients with breast cancer. J Clin Oncol. 2020; 38(6): 548-57, CrossRef.
Goetz MP, Sangkuhl K, Guchelaar H, Schwab M, Province M, Whirl‐Carrillo M, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther. 2018; 103(5): 770-7, CrossRef.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30(8): 1194-220, CrossRef.
Habano. CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers. Int J Oncol. 2009; 34(4): 1085-91, CrossRef.
Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, et al. Epigenetic regulation of vitamin D 24-hydroxylase/ CYP24A1 in human prostate cancer. Cancer Res. 2010; 70(14): 5953-62, CrossRef.
Temesvári M, Kóbori L, Paulik J, Sárváry E, Belic A, Monostory K. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther. 2012; 341(1): 294-305, CrossRef.
Pan X, Ning M, Jeong H. Transcriptional regulation of CYP2D6 expression. Drug Metab Dispos. 2017; 45(1): 42-8, CrossRef.
Triana R, Sukmawati IR, Syamsunarno MRAA, Lestari K. Higher Nrf2 level is correlated with metabolic parameters in type 2 diabetes mellitus. Indones Biomed J. 2023; 15(6): 383-90, CrossRef.
Siswanto FM, Oguro A, Arase S, Imaoka S. WDR23 regulates the expression of Nrf2-driven drug-metabolizing enzymes. Drug Metab Pharmacokinet. 2020; 35(5): 441-55, CrossRef.
Bai X, Chen Y, Hou X, Huang M, Jin J. Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev. 2016; 48(4): 541-67, CrossRef.
Oguro A, Sakamoto K, Funae Y, Imaoka S. Overexpression of CYP3A4, but not of CYP2D6, promotes hypoxic response and cell growth of Hep3B cells. Drug Metab Pharmacokinet. 2011; 26(4): 407-15, CrossRef.
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017; 19(8): 649-58, CrossRef.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5): 401-4, CrossRef.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1): W98-102, CrossRef.
Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene set knowledge discovery with Enrichr. Curr Protoc. 2021;1(3): e90, CrossRef.
Steinhaus R, Robinson PN, Seelow D. FABIAN-variant: Predicting the effects of DNA variants on transcription factor binding. Nucleic Acids Res. 2022; 50(W1): W322-9,
Kumaladewi P, Harahap WA, Nova B, Widodo I, Karsono R, Sandra F, et al. Role of estrogen receptor alpha rs3798577 polymorphism in breast carcinoma risk determination. Indones Biomed J. 2022; 14(4): 436-41, CrossRef.
Widowati W, Jasaputra DK, Sumitro SB, Widodo MA, Afifah E, Rizal R, et al. Direct and indirect effect of TNFα and IFNγ toward apoptosis in breast cancer cells. Mol Cell Biomed Sci. 2018; 2(2): 60-9, CrossRef.
Abdihalim TS, Idris AAA. Mucin level as a potential biomarker for breast cancer diagnosis. Mol Cell Biomed Sci. 2022; 6(3): 117-20, CrossRef.
Mishra A, Srivastava A, Pateriya A, Tomar MS, Mishra AK, Shrivastava A. Metabolic reprograming confers tamoxifen resistance in breast cancer. Chem Biol Interact. 2021; 347: 109602, CrossRef.
Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020; 21(9): 3233, CrossRef.
Monte AA, West K, McDaniel KT, Flaten HK, Saben J, Shelton S, et al. CYP 2D6 genotype phenotype discordance due to drug‐drug interaction. Clin Pharmacol Ther. 2018; 104(5): 933-9, CrossRef.
Smith DA, Sadler MC, Altman RB. Promises and challenges in pharmacoepigenetics. Cambridge Prism Precis Med. 2023; 1: e18, CrossRef.
Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, et al. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010; 20(8): 1020-36, CrossRef.
Wang J, Yu L, Jiang H, Zheng X, Zeng S. Epigenetic regulation of differentially expressed drug-metabolizing enzymes in cancer. Drug Metab Dispos. 2020; 48(9): 759-68, CrossRef.
Chen F, Xiao M, Hu S, Wang M. Keap1-Nrf2 pathway: A key mechanism in the occurrence and development of cancer. Front Oncol. 2024; 14: 1381467, CrossRef.
Bekele RT, Venkatraman G, Liu R-Z, Tang X, Mi S, Benesch MGK, et al. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance. Sci Rep. 2016; 6(1): 21164, CrossRef.
Wu S, Lu H, Bai Y. Nrf2 in cancers: A double‐edged sword. Cancer Med. 2019; 8(5): 2252-67, CrossRef.
Reinema F V., Sweep FCGJ, Adema GJ, Peeters WJM, Martens JWM, Bussink J, et al. Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer. Cancer Metab. 2023; 11(1): 3, CrossRef.
Ashino T, Yamamoto M, Numazawa S. Nrf2 antioxidative system is involved in cytochrome P450 gene expression and activity: A delay in pentobarbital metabolism in Nrf2-deficient mice. Drug Metab Dispos. 2020; 48(8): 673-80, CrossRef.
Zhang J, Xu HX, Zhu JQ, Dou YX, Xian YF, Lin ZX. Natural Nrf2 inhibitors: A review of their potential for cancer treatment. Int J Biol Sci. 2023; 19(10): 3029-41, CrossRef.
Gupta CL, Akhtar S, Bajpai P. In silico protein modeling: Possibilities and limitations. EXCLI J. 2014; 13: 513-5, PMID.
DOI: https://doi.org/10.18585/inabj.v17i1.3194
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
